Prosecution Insights
Prosecution Insights
5 pending office actions • 5 clients • 5 examiners • 5 art units • 0 of 5 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (60%) |
| §102 only | 1 (20%) |
| No statute on record | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FOLEY, SHANON A | 1 | 73.3% | +18.0% |
| ZARA, JANE J | 1 | 70.8% | +16.1% |
| DAVIS, RUTH A | 1 | 60.8% | +31.2% |
| DHAR, MATASHA | 1 | 44.3% | +49.4% |
| YAMASAKI, ROBERT J | 1 | 67.5% | +42.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17642054 | METHOD FOR THE PRODUCTION OF RAAV AND METHOD FOR THE IN VITRO GENERATION OF GENETICALLY ENGINEERED, LINEAR, SINGLE-STRANDED NUCLEIC ACID FRAGMENTS CONTAINING ITR SEQUENCES FLANKING A GENE OF INTEREST | YAMASAKI, ROBERT J | 9d overdue |
| 18349989 | NOVEL COMPOSITIONS BASED ON POLYINOSINIC-POLYCYTIDYLIC ACID | ZARA, JANE J | 8d overdue |
| 18546427 | GENETICALLY MODIFIED CLOSTRIDIUM STRAINS EXPRESSING RECOMBINANT ANTIGENS AND USES THEREOF | FOLEY, SHANON A | 5d overdue |
| 17767725 | METHOD FOR PREVENTING HUMAN GLANDS FROM RADIATION DAMAGE | DAVIS, RUTH A | 8d |
| 17765804 | TREATMENT OF DISEASES CAUSED BY FRAME SHIFT MUTATIONS | DHAR, MATASHA | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Livingmed Biotech | 1 |
| Highlight Therapeutics | 1 |
| MERZ THERAPEUTICS GMBH | 1 |
| Christian Kupatt | 1 |
| Bielefeld University | 1 |
| Art Unit | Apps |
|---|---|
| 1671 | 1 |
| 1637 | 1 |
| 1699 | 1 |
| 1632 | 1 |
| 1657 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18546427 | GENETICALLY MODIFIED CLOSTRIDIUM STRAINS EXPRESSING RECOMBINANT ANTIGENS AND USES THEREOF | Livingmed Biotech S.r.l. | FOLEY, SHANON A | 1671 | Other | Non-Final OA | 5d overdue | Pending | Aug 14, 2023 |
| 18349989 | NOVEL COMPOSITIONS BASED ON POLYINOSINIC-POLYCYTIDYLIC ACID | Highlight Therapeutics, S.L. | ZARA, JANE J | 1637 | §102 | Non-Final OA | 8d overdue | Pending | Jul 11, 2023 |
| 17767725 | METHOD FOR PREVENTING HUMAN GLANDS FROM RADIATION DAMAGE | Merz Therapeutics GmbH | DAVIS, RUTH A | 1699 | §103 | Non-Final OA | 8d | Pending | Apr 08, 2022 |
| 17765804 | TREATMENT OF DISEASES CAUSED BY FRAME SHIFT MUTATIONS | Christian Kupatt | DHAR, MATASHA | 1632 | §103 | Final Rejection | — | Pending | Mar 31, 2022 |
| 17642054 | METHOD FOR THE PRODUCTION OF RAAV AND METHOD FOR THE IN VITRO GENERATION OF GENETICALLY ENGINEERED, LINEAR, SINGLE-STRANDED NUCLEIC ACID FRAGMENTS CONTAINING ITR SEQUENCES FLANKING A GENE OF INTEREST | UNIVERSITÄT BIELEFELD | YAMASAKI, ROBERT J | 1657 | §103 | Non-Final OA | 9d overdue | Pending | Mar 10, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial